ArticleTranslational lung cancer research2025

Lorlatinib in ALK-positive non-small cell lung cancer: final survival data that reshape the therapeutic landscape.

Yuki KatayamaPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.